Search research articles
Contact Us
Filters
Showing results (51-60 of 60) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 60 results.
Genome Medicine
|
January 6, 2022
Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial
Jung Yong Hong, Hee Jin Cho, Jason K Sa, et al.
Nature Communications
|
November 20, 2014
Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing
Swee Seong Wong, Kyoung-Mee Kim, Jason C Ting, et al.
Nature Medicine
|
July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
European Urology Oncology
|
May 1, 2022
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
María Dolores Fenor de la Maza, Khobe Chandran, Jan Rekowski, et al.
Cell Biochemistry and Biophysics
|
July 8, 2009
Positive allosteric interaction of structurally diverse T-type calcium channel antagonists
Victor N Uebele, Cindy E Nuss, Steven V Fox, et al.
Cell Reports
|
December 24, 2016
Inhibition of RORγT Skews TCRα Gene Rearrangement and Limits T Cell Repertoire Diversity
Yanxia Guo, Kenzie D MacIsaac, Yi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
Aude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
Molecular Cancer Therapeutics
|
December 30, 2021
Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
Peter Georgiev, Eric S Muise, Douglas E Linn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
Nature Medicine
|
April 21, 2015
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu, Jeeyun Lee, Michael Nebozhyn, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 60) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 60 results.
Genome Medicine
|
January 6, 2022
Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intra-tumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial
Jung Yong Hong, Hee Jin Cho, Jason K Sa, et al.
Nature Communications
|
November 20, 2014
Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencing
Swee Seong Wong, Kyoung-Mee Kim, Jason C Ting, et al.
Nature Medicine
|
July 10, 2023
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
Martin Gutierrez, Wei-Sen Lam, Matthew D Hellmann, et al.
European Urology Oncology
|
May 1, 2022
Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer
María Dolores Fenor de la Maza, Khobe Chandran, Jan Rekowski, et al.
Cell Biochemistry and Biophysics
|
July 8, 2009
Positive allosteric interaction of structurally diverse T-type calcium channel antagonists
Victor N Uebele, Cindy E Nuss, Steven V Fox, et al.
Cell Reports
|
December 24, 2016
Inhibition of RORγT Skews TCRα Gene Rearrangement and Limits T Cell Repertoire Diversity
Yanxia Guo, Kenzie D MacIsaac, Yi Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 30, 2024
Association of Tumor Mutational Burden and PD-L1 with the Efficacy of Pembrolizumab with or without Chemotherapy versus Chemotherapy in Advanced Urothelial Carcinoma
Aude Fléchon, Rafael Morales-Barrera, Thomas Powles, et al.
Molecular Cancer Therapeutics
|
December 30, 2021
Reverse Translating Molecular Determinants of Anti-Programmed Death 1 Immunotherapy Response in Mouse Syngeneic Tumor Models
Peter Georgiev, Eric S Muise, Douglas E Linn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials
Joaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
Nature Medicine
|
April 21, 2015
Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes
Razvan Cristescu, Jeeyun Lee, Michael Nebozhyn, et al.
Page
of 6